CAS: 1313725-88-0; (S)-1-(1-(Imidazo[1,2-A]Pyridin-6-yl)Ethyl)-6-(1-Methyl-1H-Pyrazol-4-yl)-1H-[1,2,3]Triazolo[4,5-B]Pyrazine

该化合物是一个复杂的有机化合物,其特点是多环结构结构,包括imidazole,pyrazole和三联苯酸;该化合物的特征是一个手性中心,有助于其立体化学,能够影响其生物活动和相互作用;通常通过多步有机反应合成,通常涉及混合反应和循环过程;氮原子在其结构中的存在表明氢与金属离子的结合和协调潜力,这可能与医药化学和物质科学有关;该化合物可能具有药性特性,使其对药物的发现和开发,特别是针对特定生物路径具有兴趣;其溶性,稳定性和再活性可因环境条件和功能组的存在而变化.

结构式图片

欧盟法规

ECHA物质C&L通报

上下游产品

1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine 1-(imidazo[1,2-a]pyridin-6-yl)ethanamine methyl 6-aminonicotinoate pyridinecarboxylatemethyl 6-imidazo1,2-apyridinecarboxylate

合成工艺路线路线简述

  • 合成目标产物 Volitinib 主要起始原料 6-Aminonicotinic Acid
  • (文献来源)合成步骤主要原料 6-Aminonicotinic Acid
📜1-咪唑并[1,2-A]吡啶-6-基乙酮置于sodium Tetraborate Decahydrate,磷酸吡哆醛,氨,Amine Transaminase-436,异丙基氨盐酸盐,Potassium Carbonate,溶剂黄146,N,N-二异丙基乙胺,Sodium Hydroxide,Sodium Nitrite体系中,用 N-甲基吡咯烷酮,二氯甲烷,水,二甲基亚砜,仲丁醇 用作溶剂,化学反应 82.08H,反应生成沃利替尼
参考文献: Improved Method For The Manufacture Of 3-[(1S)-1-Imidazo[1,2-A]Pyridin-6-Ylethyl]-5-(1-Methylpyrazol-4-yl)Triazolo[4,5-B]Pyrazine And Polymorphic Forms Thereof[fr] Procédé Amélioré Pour La Fabrication De 3-[(1S)-1-Imidazo[1,2-A]Pyridin-6-Yléthyl]-5-(1-Méthylpyrazol-4-yl)Triazolo[4,5-B]Pyrazine Et Ses Formes Polymorphes
标题: Improved Method For The Manufacture Of 3-[(1S)-1-Imidazo[1,2-A]Pyridin-6-Ylethyl]-5-(1-Methylpyrazol-4-yl)Triazolo[4,5-B]Pyrazine And Polymorphic Forms Thereof[fr] Procédé Amélioré Pour La Fabrication De 3-[(1S)-1-Imidazo[1,2-A]Pyridin-6-Yléthyl]-5-(1-Méthylpyrazol-4-yl)Triazolo[4,5-B]Pyrazine Et Ses Formes Polymorphes
摘要:这项规范通常涉及一种改进的方法,用于制造3-[(Ls)-L-咪唑[1,2-A]吡啶-6-基乙基]-5-(L-甲基吡唑-4-基)三唑并[4,5-B]吡嗪(I),或其药用盐;其多晶形式;以及在制造这类化合物及其盐时有用的中间体.公式(I).

海关参考信息

专利信息


专利号:US-12390420-B1
优先权日:2024-10-22
标题 :Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof
发明人:EGUCHI MASAKATSU
权利人:BRYET US INC
摘要:The present disclosure provides compositions and methods for delivering therapeutic agents to particular tissues or cells in a subject. The composition disclosed herein combines unique properties of porous micro- or nano-particles with host-guest chemistry provided by functionalized silicon particle, offering a versatile approach to addressing the challenges associated with delivering therapeutic agents to target tissues or sites within the body. The present disclosure also provides a method for synthesizing a composition capable of delivering therapeutic agents to particular tissues or cells in a subject.

专利号:CN-116209754-A
优先权日:2020-09-28
标题 :Engineered biocatalysts and methods for the synthesis of chiral amines

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Li R, Liu X, Xu Y, Zhao J, Zhong W, Gao X, Chen M, Wang M. Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report. Thorac Cancer. 2024 Sep 29. doi: 10.1111/1759-7714.15459. Epub ahead of print. study group. Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study. Lancet Respir Med. 2024 Sep
10:S2213-2600(24)00211-X. doi: 10.1016/S2213-2600(24)00211-X. Epub ahead of print.
14:1450855. doi: 10.3389/fonc.2024.1450855.

合成参考文献


参考文献:10.1007/s40291-021-00568-w
摘要:Dong Y, Xu J, Sun B, Wang J, Wang Z. MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review. Molecular Diagnosis & Therapy. 2022 Mar 10;26(2):203–27. doi: 10.1007/s40291-021-00568-w.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知